EUVIMEDEUVIMED entdecken
LeserbriefMultizentrische Studie

Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study)

Sofia Tzoumpa iD, Saskia Ingen-Housz-Oro iD, Adèle de Masson, Anne Pham-Ledard, Tarik El Aarbaoui, Olivier Dereure, Gaëlle Quereux, Sarah Faiz, Marine de Vicq de Cumptich, Caroline Ram-Wolff, Raphaël Janela-Lapert, Emmanuella Guenova und 10 weitere

British Journal of Dermatology · 20.06.2024 · 191 (1) · 143-144

DOI: 10.1093/bjd/ljae153 ↗

Kurz gefasst

Leserbrief in der Zeitschrift British Journal of Dermatology, online erschienen am 25.04.2024. Verfasst von Sofia Tzoumpa und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Henri-Mondor University Hospital, AP-HP, Créteil, France. Hauptthemen laut MEDLINE: Sezary Syndrome, Antibodies, Monoclonal, Humanized, Skin Neoplasms, Disease Progression. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The results of this study suggest that progressive discontinuation of mogamulizumab (Moga) should be considered once a response is obtained in patients with Sézary syndrome, even after a short treatment duration. This may minimize the risk of adverse effects, costs and resistance to Moga. Additionally, our study emphasizes that Moga rechallenge should be encouraged as a first choice in relapsing patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sezary SyndromeAntibodies, Monoclonal, HumanizedSkin NeoplasmsDisease ProgressionHumansRetrospective StudiesMaleFemaleAgedMiddle AgedWithholding TreatmentAged, 80 and overAdult

Substanzen

Antibodies, Monoclonal, Humanizedmogamulizumab

Autor:innen und Institutionen

  • Department of Dermatology, Henri-Mondor University Hospital, AP-HP, Créteil, France.
  • Paris Est Créteil University, EpiDermE, Créteil, France.
  • French Cutaneous Lymphomas Study Group (GFELC), France.

ORCID-Profile: Sofia Tzoumpa, Saskia Ingen-Housz-Oro, Maël Blanchard, Marie Beylot-Barry

Zitieren

APA

Tzoumpa, S., Ingen-Housz-Oro, S., de Masson, A., Pham-Ledard, A., El Aarbaoui, T., Dereure, O., Quereux, G., Faiz, S., de Vicq de Cumptich, M., Ram-Wolff, C., Janela-Lapert, R., Guenova, E., Lheure, C., Le Corre, Y., Adamski, H., Blanchard, M., Bonnet, N., Amatore, F., Grange, F., …, & Beylot-Barry, M. (2024). Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study). British Journal of Dermatology, 191(1), 143-144. https://doi.org/10.1093/bjd/ljae153

Vancouver

Tzoumpa S, Ingen-Housz-Oro S, de Masson A, Pham-Ledard A, El Aarbaoui T, Dereure O, et al. Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study). British Journal of Dermatology. 2024;191(1):143-144. doi:10.1093/bjd/ljae153

BibTeX
@article{Tzoumpa2024,
  author = {Tzoumpa, Sofia and Ingen-Housz-Oro, Saskia and de Masson, Adèle and Pham-Ledard, Anne and El Aarbaoui, Tarik and Dereure, Olivier and Quereux, Gaëlle and Faiz, Sarah and de Vicq de Cumptich, Marine and Ram-Wolff, Caroline and Janela-Lapert, Raphaël and Guenova, Emmanuella and Lheure, Coralie and Le Corre, Yannick and Adamski, Henri and Blanchard, Maël and Bonnet, Nathalie and Amatore, Florent and Grange, Florent and Troin, Laura and Bagot, Martine and Beylot-Barry, Marie},
  title = {Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study)},
  journal = {British Journal of Dermatology},
  year = {2024},
  volume = {191},
  number = {1},
  pages = {143--144},
  doi = {10.1093/bjd/ljae153}
}
Kostenlos starten →